Summary & Overview
HCPCS M0246: Bamlanivimab and Etesevimab IV Infusion in Home
HCPCS Level II code M0246 designates an in-home intravenous infusion service for the monoclonal antibody combination bamlanivimab and etesevimab, and includes post-infusion monitoring. This code matters nationally as monoclonal antibody therapies have been deployed for outpatient management of certain infectious diseases, and in-home infusion options affect access, utilization patterns, and payer coverage policies across commercial and government plans. Key payers discussed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will learn what the code covers clinically and operationally, how payers approach coverage for in-home monoclonal antibody infusions, and where to find policy and billing considerations relevant to claims processing. The publication provides benchmarks and context for service line planning, describes typical sites of service and service type, and summarizes common modifiers and payer considerations where available. Data not available in the input for associated taxonomies, ICD-10 diagnoses, related codes, and detailed payer-specific rates is noted where applicable.
Billing Code Overview
HCPCS Level II code M0246 describes an intravenous infusion of bamlanivimab and etesevimab delivered in the beneficiary's home or residence. The code includes both the infusion administration and post-administration monitoring provided on-site. The service type is therapeutic monoclonal antibody infusion. The typical site of service is home or residence, including a beneficiary's home that has been made provider-based to a hospital during the COVID-19 public health emergency.
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult outpatient with mild to moderate COVID-19 infection at high risk for progression to severe disease due to age or comorbidities (for example, age ≥65 years, diabetes, chronic lung disease, immunosuppression, or obesity). The patient has a confirmed positive SARS-CoV-2 test and meets clinical eligibility for monoclonal antibody therapy. A clinician (physician, nurse practitioner, or physician assistant) evaluates the patient via telehealth or in-person, documents indication and consent, and schedules a home infusion visit when the patient cannot safely attend an infusion center or when home administration is preferred.
A trained infusion nurse or qualified clinician visits the patient’s home or residence, prepares bamlanivimab and etesevimab per manufacturer and institutional protocols, administers the intravenous infusion, and provides post-administration monitoring on site for the recommended observation period. The service includes drug administration, intravenous access, infusion monitoring, management of expected infusion-related reactions, and documentation. During declared public health emergency policies, a beneficiary’s home may be treated as provider-based to the hospital for billing purposes, and this code covers the combined infusion and post-administration monitoring delivered in the home or residence setting.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
22 | Increased procedural service | When the work required to provide the infusion is substantially greater than typical (for example, extended time for difficult venous access or significant care coordination in the home). |